Skip to main content
Genes & Nutrition logoLink to Genes & Nutrition
. 2007 Sep 27;2(2):209–223. doi: 10.1007/s12263-007-0051-4

Characterization of intestinal inflammation and identification of related gene expression changes in mdr1a−/− mice

Y EM Dommels 1,5, C A Butts 1,, S Zhu 2, M Davy 3, S Martell 1, D Hedderley 1, M PG Barnett 4, W C McNabb 4, N C Roy 4
PMCID: PMC2474946  PMID: 18850176

Abstract

Multidrug resistance targeted mutation (mdr1a−/−) mice spontaneously develop intestinal inflammation. The aim of this study was to further characterize the intestinal inflammation in mdr1a−/− mice. Intestinal samples were collected to measure inflammation and gene expression changes over time. The first signs of inflammation occurred around 16 weeks of age and most mdr1a−/− mice developed inflammation between 16 and 27 weeks of age. The total histological injury score was the highest in the colon. The inflammatory lesions were transmural and discontinuous, revealing similarities to human inflammatory bowel diseases (IBD). Genes involved in inflammatory response pathways were up-regulated whereas genes involved in biotransformation and transport were down-regulated in colonic epithelial cell scrapings of inflamed mdra1−/− mice at 25 weeks of age compared to non-inflamed FVB mice. These results show overlap to human IBD and strengthen the use of this in vivo model to study human IBD. The anti-inflammatory regenerating islet-derived genes were expressed at a lower level during inflammation initiation in non-inflamed colonic epithelial cell scrapings of mdr1a−/− mice at 12 weeks of age. This result suggests that an insufficiently suppressed immune response could be crucial to the initiation and development of intestinal inflammation in mdr1a−/− mice.

Keywords: Colon, Gene expression, Intestinal Inflammation, Mice

Introduction

Inflammatory Bowel Disease (IBD) refers to two diseases that are characterized by chronic inflammation of the gastrointestinal tract: Crohn’s Disease (CD) and Ulcerative Colitis (UC). Both CD and UC share overlap in disease pathology, but also have distinct pathological features. For example, CD can affect any part of the gastrointestinal tract whereas UC is confined to the colon and rectum. The inflammation seen in CD is typically discontinuous, segmental and transmural, involving all layers of the intestinal wall. The lesions in UC are continuous and the inflammation is superficial, only affecting the mucosal layer of the colonic wall [27].

The exact etiology and pathogenesis of IBD is still unclear, but there is strong epidemiological evidence for a genetic contribution to disease susceptibility. Several candidate IBD susceptibility genes have been identified, including a multidrug resistance gene, MDR1 [8, 19]. P-glycoprotein 170, encoded by the human MDR1 (ABCB1) gene and the mouse mdr1a (abcb1a) and mdr1b (abcb1b) genes, belongs to a family of transmembrane transporters, known as ATP-binding cassette transporters [11]. In the gastrointestinal tract, MDR1 is expressed at the apical surface of intestinal epithelial cells, where it is proposed to actively pump toxins from inside gut cells back into the intestinal lumen, thus decreasing their absorption and bioavailability [3, 11]. The MDR1 gene is located on chromosome 7q, a region for which there is linkage to IBD. Several single nucleotide polymorphisms (SNPs) in MDR1 have been associated with reduced MDR1 activity and have been linked to IBD in some, but not all, populations [4, 12, 25]. Microarray data have also revealed MDR1 as a novel susceptibility gene for IBD. Two independent microarray studies in humans demonstrated a lower expression of MDR1 in colonic biopsies from affected UC and CD patients compared to control subjects [16, 17].

The finding that genetically engineered mdr1a−/− mice, with a targeted mutation of the mdr1a gene [24], spontaneously develop intestinal inflammation [20] is further evidence that reduced intestinal MDR1 expression or activity may be an important factor in the pathogenesis of IBD. The inflammation seen in mdr1a−/− mice was originally classified as similar to UC, but more recent findings suggest a closer resemblance to CD [2]. Observations in mdr1a−/− mice that support this suggestion include the location of inflammation (both colon and small intestine), the nature of inflammation (superficial and transmural) and the type of immune response (T-helper cell type 1 response; interferon gamma, IFN-γ) [2, 18].

The mechanistic defect causing inflammation in mdr1a−/− mice is unclear, but oral antibiotic treatment both prevented and therapeutically reversed inflammation in mdr1a−/− mice, demonstrating the requirement for bacterial flora in the initiation and progression of inflammation in these mice [20]. In addition, infection with Helicobacter bilis has been shown to accelerate the development of inflammation, whereas H. hepaticus infection delayed the development of inflammation in mdr1a−/− mice [18]. We hypothesize that decreased intestinal efflux transport in mdr1a−/− mice may lead to a buildup of bacterial products, resulting in an exaggerated or insufficiently suppressed immune response.

The aim of this study was to further characterize the nature, onset and development of inflammation in mdr1a−/− mice to better understand the initiation and progression of inflammation in these mice. Sequential histological analysis of intestinal samples was performed over time to verify the time of onset, incidence, location, nature and degree of inflammation. High-density oligonucleotide microarrays were used to identify gene expression changes in colonic epithelial cell scrapings to gain new insight into the immune response associated with initiation and development of inflammation in mdr1a−/− mice.

Materials and methods

Animals and diet

A total of 48 male mdr1a−/− (FVB.129P2-PAbcb1atm1Bor N7) and 48 male FVB/NTac control mice were purchased from Taconic (Hudson, NY, USA) at 4–5 weeks of age. The mice were initially housed in pairs but, due to fighting, were subsequently housed individually in shoebox-style cages containing untreated wood shavings (Cairns Bins, Palmerston North, NZ) with a plastic tube for environmental enrichment. The animal room was controlled and maintained at a temperature of ∼22°C, humidity of ∼50% and a 12 h light/dark cycle. All mice were given free access to water and offered an AIN-76A powdered diet prepared in-house (Table 1) ad libitum.

Table 1.

Composition of the AIN-76A diet

Dietary ingredient Percentage in the diet (%)
Caseina 20
dl-methionineb 0.30
Sucrosec 50
Dextrind 15
Arbocel, non-nutritive bulke 5
Corn oilf 5
Choline bitartrateg 0.2
AIN-76A Mineral Mixh 3.5
AIN-76A Vitamin Mixi 1
Ethoxyquinj 0.01

aAlacid, Lactic casein 30 mesh, NZMP Ltd, Wellington, New Zealand

bSigma, Sigma-Aldrich Inc, St Louis, MO, USA

cCaster sugar, Chelsea, New Zealand Sugar Company Limited, Auckland, New Zealand

dWheaten cornstarch, Golden Harvest, Primary Foods Ltd, Auckland, New Zealand

eArbocell B600, J. Rettenmaier & Sohne GmbH + Co, Rosenberg, Germany

fTradewinds, Davis Trading, Palmerston North, New Zealand

gSigma, Sigma-Aldrich Inc, St Louis, MO, USA

hPrepared in-house based on the AIN-76A diet formulation [23]

iPrepared in-house based on the AIN-76A diet formulation [23]

jSigma, Sigma-Aldrich Inc, St Louis, MO, USA

Experimental design

The objective of this experiment was to study the initiation and development of intestinal inflammation and associated changes in gene expression in mdr1a−/− mice fed a standard diet as a prerequisite to developing this mouse model for future nutrigenomics studies to explore the effects of changes in nutrition on the development and etiology of IBD. Therefore, for sequential sampling, both mdr1a−/− and FVB control mice were randomly divided into eight sampling groups (9, 12, 16, 22, 25, 27, 29 and 31 weeks of age). All mice were weighed twice a week and carefully monitored for disease symptoms (weight loss, soft faeces, faecal bleeding, posture, gait and inactivity). From around 19 weeks of age, some mortality occurred in the mdr1a−/− mice so the last group was sampled at 29 instead of 31 weeks of age. Five days prior to the sampling day those mice allocated for sampling were placed in metabolism cages, offered 3.5–4.0 g/day of the AIN-76A diet and food consumption was measured. Food refusals and spillage were measured to calculate intake. On the last day, mice were fasted overnight (from 3 p.m.) and food was offered 2–4 h prior to sampling in three staggered groups of four mice. All mice were euthanased by CO2 asphyxiation. The intestine was quickly removed, cut open lengthwise and flushed with 0.9% NaCl to remove any trace of digesta. The intestine was subdivided into duodenum, jejunum, ileum and colon. Two pieces of intact tissue (three for jejunum) at different distal locations per region were collected and stored at room temperature in formalin (10% neutral buffered) for histological analysis. Another intact piece of colon tissue (in between the sections for histology) was snap-frozen in liquid nitrogen and stored at −80°C to measure myeloperoxidase (MPO) activity, a marker of neutrophil infiltration. The epithelial layer of the proximal half of each intestinal region was scraped off, snap-frozen in liquid nitrogen and stored at −80°C for RNA extraction. The experimental procedures for this trial were reviewed and approved by the Crown Research Institute Animal Ethics Committee in Palmerston North, New Zealand according to the Animal Welfare Act 1999.

Histology

The two intact pieces from different areas of each intestinal section (duodenum, jejunum, ileum or colon) were fixed in 10% neutral buffered formalin, embedded in a paraffin block and processed for sectioning. All tissue sections were sliced to obtain sections of 5 μm thickness then stained with haematoxylin and eosin for light microscopic examination. The tissue sections were scored for the following aspects of inflammation: inflammatory lesions (mononuclear cell infiltration, neutrophil infiltration, eosinophil infiltration, plasmocyte infiltration, fibrin exudation and lymphangiectasis), tissue destruction (enterocyte loss, ballooning degeneration, edema and mucosal atrophy) and tissue reparation (hyperplasia, angiogenesis, granulomas and fibrosis). A rating score between 0 (no change from normal tissue) and 3 (lesions involved most areas and all the layers of the intestinal section including mucosa, muscle and omental fat) was given for each aspect of inflammatory lesion, tissue destruction and tissue reparation. The sum of inflammatory lesions (2×), tissue destruction and tissue reparation score was used to represent the total histological injury score (HIS) for each intestinal section. The sum of the inflammatory lesions was multiplied by 2 to give more weight to this value as the inflammation was mainly characterized by inflammatory lesions.

Myeloperoxidase activity

A surrogate marker of inflammation, MPO activity, was also assessed in an intact piece of colon tissue from non-inflamed and inflamed mice using a colourimetric assay as described by Grisham et al. [9]. Colon tissue from 12 and 25 week old FVB and mdr1a−/− was used. The tissue was thawed, weighed and homogenized in a buffer (1 ml of buffer per 50 mg of tissue) containing 200 mM sucrose, 20 mM Tris, 1 mM dithiothreitol and a protease inhibitor (complete protease inhibitor cocktail tablets, Roche Diagnostics, New Zealand) (pH 7.4 with HCl). The homogenate was centrifuged at 20,000g for 20 min at 4°C and the resulting pellet was dissolved in acetate–HETAB buffer (pH 6.0) and sonicated (2 × 10 s) to solubilize MPO. MPO catalyzes the oxidation of 3,3′,5,5′-tetramethylbenzidine by H2O2 to yield a blue chromogen with a wavelength maximum at 655 nm. One unit of activity was defined as the amount of enzyme present that produces a change in absorption per minute of 1.0 at 37°C in the final reaction volume containing sodium acetate. Protein content of the colon samples was determined spectrophotometrically using the bicinchoninic acid Protein Assay Kit (Pierce) with bovine serum albumin as a standard.

RNA isolation

Total RNA was isolated from colonic epithelial cell scrapings of both 12 and 25 week old mdr1a−/− and FVB mice using TRIzol (Invitrogen, Auckland, NZ) according to the manufacturer’s protocol. Total RNA was further purified using the Qiagen RNeasy Mini Kit (Biolab, Palmerston North, NZ). RNA quality was checked with a Bioanalyzer (Agilent Technologies) and the concentration was measured using the Nanodrop (Nanodrop technologies through Biolab). Samples with an OD 260/280 ratio >2.0 and a Bioanalyzer 28 s/18 s peak ratio >1.2 were considered acceptable for further analysis. Eight RNA pools were made for gene expression profiling. Each pool consisted of 2 μg purified total RNA extracted from colonic epithelial cell scrapings per animal with two to three animals per pool. There were two pools per sampling group; these included 12 and 25 week old mdr1a−/− and FVB mice (mdr1a−/−12, FVB12, mdr1a−/−25 and FVB25). A reference pool was made using an equal amount of total purified RNA extracted from colonic epithelial cell scrapings from all individual animals.

cDNA and fluorescent cRNA synthesis

The Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies Inc., Palo Alto, CA, USA) was used to synthesize cDNA and fluorescent cRNA. Labelled cRNA was made on the same day for all pools, including the reference pool. Five hundred nanogram of purified total RNA from each pool was reverse transcribed into cDNA using T7 promotor primer and MMLV-RT enzyme according to the manufacturer’s protocol. Either cyanine 3-CTP or cyanine 5-CTP (Perkin-Elmer) was added to each pool. A reference design, including a dye-swap, was used. For each sampling group, one of the pools was labelled with Cy5 while the second pool was labelled with Cy3. The reference pool was also labelled with either Cy5 or Cy3, depending on the labelling of the sample pool. Quality and quantity of the cRNA samples was assessed as described above, respectively before continuing with the hybridization.

Microarray hybridization and scanning

The in situ Hybridization Kit-plus (Agilent Technologies) was used to hybridize cRNA samples to Agilent Technologies Mouse G4121A - 22 k 60mer oligo arrays. 0.75 μg Cy3 labelled cRNA and 0.75 μg Cy5 labelled cRNA was hybridized onto the microarray according to the manufacturer’s protocol. The cRNA was spiked with control targets to ensure correct hybridization. Hybridization was performed in an Agilent hybridization oven for 17 h at 60°C, rotating at 4 rpm in the dark. After hybridization, slides were washed and dried according to the manufacturer’s protocol and scanned using the Axon GenePix 4200A scanner at a photomultiplier tube (PMT) voltage of 450. Spot identification and quantification was performed using GenePix 7.0 software.

Microarray data analysis

Statistical analysis was performed independently by two different researchers using two different software analysis approaches. The first researcher used GeneSpring GX 7.3 expression analysis software (Agilent Technologies). Data were transformed to correct for the dye-swap and a global normalization (Lowess) was applied. A cross gene error model was used to filter out less precise measurements based on control strength. Furthermore, genes with a probability value superior to 0.3 were filtered out prior to analysis. A list of differentially expressed genes was generated for each comparison of interest (mdr1a−/−12 vs. FVB12 and mdr1a−/−25 vs. FVB25) via a volcano plot, using the following criteria; probability value inferior to 0.05 and fold-change superior to 2.

The second researcher used Linear models for microarray analysis (Limma) within the Bioconductor framework to independently analyze the experiment. Prior to analysis spots manually flagged as bad were filtered out before applying a within slide global loess normalization (without background correction). For each comparison a list of differentially expressed gene candidates was generated using moderated t statistics and false discovery rate control with alpha = 0.05 as a statistical filtering criteria.

Only data that fulfilled the criteria of the Genespring analysis and were in the top 100 list of genes ranked using the moderated t statistics and false discovery rate control in Limma were considered as true differentially expressed genes. Only results from the Limma data analysis are shown.

Quantitative real-time polymerase chain reaction

Quantitative real-time polymerase chain reaction (RT-PCR) was performed to confirm changes in mRNA levels identified using microarray analysis. cDNA was synthesized from 1 μg of total RNA from all sample pools and all individual animals using SuperScript II reverse transcriptase (Invitrogen, NZ). SYBR Green quantitative PCR was performed on the real-time rotary analyzer Rotor-Gene 3000 (Corbett Research, Australia), using the Brilliant SYBR Green QPCR Core Reagent Kit (Stratagene, NZ) according to the manufacturer’s protocol. One microliter of 100× diluted cDNA and 1.25 μl of a 1:3000 dilution of the SYBR green dye was used in each 25 μl reaction, with a final primer concentration of 400 nM. The following cycles were performed; 1 × 10 min at 95°C, 40 amplification cycles (40 × 30 s 95°C, 60 s 55°C and 60 s 72°C). A dissociation curve was run with each PCR reaction to verify the absence of primer-dimers and genomic DNA amplification. Data were normalized against the housekeeping genes hypoxanthine phosphoribosyltransferase 1 (HPRT1) and/or calnexin (CANX), whose expression levels were unaffected by the different sample conditions (array data not shown).

Primers were designed using the PrimerSelect software (DNASTAR Lasergene). The following primers (GeneWorks Ltd, Auckland, NZ), were used: CYP4B1: lower 5′–ACA GGT GGG TAG AGG CGG AAG C-3′, upper 5′-ACC AGC AGC GAT GTA GGG AGG AG-3′; SULT1C1: lower 5′-TCG CCG GCA CTT CTC TAC ATC A-3′, upper 5′-GAT CCC ACT GCA GGC TCC AAC T-3′; NCF4: lower 5′-CAT GAT GGC CCC TTG TGG AGA-3′, upper 5′-TGC CGG TCT GCG TGC TGA T-3′; REG3A: lower 5′-AGC TGT TTC CTG TTC TCT TCA CCA-3′, upper 5′-TAT ACC CTC CGC ACG CAT TAG TTG-3′; REG3G: lower 5′-AAG GGC CAG AGA AGG AGA AAA TCA-3′, upper 5′-TCA CTG TGG TAC CCT GTC AAG AGC-3′; IGFBP7: lower 5′-CAG CAC CCA GCC CGT TAC TTC-3′, upper 5′-ATC CCA ACC CCT GTC CTC ATC T-3′; H2DMB1: lower 5′-CCT TGG TTC CGG GTT CTG CTC T-3′, upper 5′-TGG GCC TGG GCT TCA TCA TCT-3′; CANX: lower 5′-GCT CCA AAC CAA TAG CAC TGA AAG G-3′, upper 5′-GCA GCG ACC TAT GAT TGA CAA CC-3′; HPRT1: lower 5′-GAG GTC CTT TTC ACC AGC AAG CT-3′, upper 5′-TGA CAC TGG TAA AAC AAT GCA AAC TTT G-3′. A standard curve for all genes including reference genes was generated using serial dilutions of a pooled sample (cDNA from all sample pools) and was included in each run. The mRNA concentrations were determined from the appropriate standard curve. Analysis of each different sample was performed in duplicate per run. Each pooled sample was validated once. The data for the individual animals are the average of two independent runs with duplicate values for each run. To obtain final results, the ratio between the gene of interest and the reference genes (quantified in the same run) was determined and compared between the different conditions (mdr1a−/−12 vs. FVB12 and mdr1a−/−25 vs. FVB25).

Statistics

All statistical analyses (body weight, food intake, histology scores, MPO activity and RT-PCR data between individual animals) were performed in GenStat (8th edition, VSN International, Hemel Hempstead, UK, 2005). One-way ANOVA was used to detect significant differences between the groups. Log transformed values were used for the statistical analysis of the HIS, MPO activity and relative mRNA expression (RT-PCR) data. A probability value less than 0.05 was regarded as significant.

Results

Animal body weight and food intake

The average body weight of the 4 to 5 weeks old mdr1a−/− and FVB mice was comparable at the beginning of the experiment, respectively 20.9 ± 1.4 and 20.6 ± 1.2 g. During the study, weight loss was observed in mdr1a−/− mice, which led to a lower average body weight of the mdr1a−/− mice compared to the FVB mice at 12, 22, 25, 27 and 29 weeks of age. This was only significant (P < 0.05) at 22 weeks of age (Table 2). Food intake was not significantly different between mdr1−/− and FVB mice at any time point of the study (Table 2).

Table 2.

Body weight, food intake and myeloperoxidase (MPO) activity of mdr1a−/− and FVB mice sampled at 9, 12, 16, 22, 25, 27 and 29 weeks of age

Age (weeks) Body weight (g)a Food intake (g/day)b MPO activityc
mdr1a−/− mice FVB mice mdr1a−/− mice FVB mice mdr1a−/− mice FVB mice
9 25.5 ± 0.5 25.2 ± 0.5 2.8 ± 0.1 2.6 ± 0.1
12 25.6 ± 0.7 26.7 ± 0.7 2.6 ± 0.1 2.9 ± 0.1 20.0 ± 13.6 5.4 ± 1.8
16 30.0 ± 1.3 28.3 ± 1.6 2.8 ± 0.1 2.8 ± 0.1
22 26.5 ± 1.6* 31.6 ± 0.9 2.5 ± 0.2 2.7 ± 0.1
25 25.5 ± 0.8** 31.4 ± 2.6 2.8 ± 0.3 3.2 ± 0.2 40.6 ± 13.2* 8.3 ± 2.2
27 31.7 ± 1.8 32.8 ± 1.9 3.4 ± 0.2 3.5 ± 0.1
29 27.0 ± 1.2 31.6 ± 1.3 2.7 ± 0.4 2.9 ± 0.2

Data are shown as average ± standard error per group of mice sampled

aBody weight was measured on the sampling day, 2–4 h after food was returned following fasting

bFood intake was measured during the 5 days prior to sampling, when the mice were fed restricted amounts of food (3.5–4 g/day)

cMPO activity was measured in intact colon samples of 12 and 25 weeks old mdr1a−/− and FVB mice

P < 0.05 mdr1a−/− versus FVB mice from the same age (1-way ANOVA)

** Marginal difference between strains (0.05 < < 0.10)

Time of onset and incidence of inflammation

We observed no signs of intestinal inflammation in any of the FVB mice. The first mdr1a−/− mouse with histological signs of intestinal inflammation was sampled at 16 weeks of age, but disease symptoms were already observed at an earlier age in this mouse (lower mobility at 13 weeks of age, diarrhea at 14 weeks of age and weight loss at 15 weeks of age). Although the time of onset of inflammation was variable between the mdr1a−/− mice, the first visible signs of intestinal inflammation were observed in most mice between 16 and 27 weeks of age. The incidence of intestinal inflammation increased over time and between 25 and 29 weeks of age, all but one of the mice left in the study had developed inflammation by the time they were sampled (Table 3).

Table 3.

Time of onset and incidence of inflammation in mdr1a−/− mice

Age in weeks 9 12 16 22 25 27 29
Number of mice sampled
 mdr1a−/− mice (total: 40a) 6 6 6 8 6 3 5
 FVB mice (total: 47b) 6 5 6 6 6 6 12
Number of mice with inflammationc
 mdr1a−/− mice 0 0 1 6 6 3 4
 FVB mice 0 0 0 0 0 0 0
Incidence of inflammation (%)
 mdr1a−/− mice 0 0 17 75 100 100 80
 FVB mice 0 0 0 0 0 0 0

aEight mdr1a−/− mice died during the experiment. Three mdr1a−/− mice died at the start of the experiment due to fighting whilst the other five mdr1a−/− mice died during the course of the experiment at 19 (1), 20 (2), 21(1) and 26 (1) weeks of age. Three of these mice were sampled and scored for histological signs of inflammation. Their total HIS in the colon varied between 11 and 18, indicating that these mice died due to inflammatory distress

bOne FVB mouse died at the start of the experiment due to fighting

cMice were regarded as inflamed when their histological injury score in at least 1 of the different intestinal regions was more than 3.5 (all FVB mice had a HIS in either duodenum, jejunum, ileum or colon less then or equal to 3.5)

Location, grade and nature of inflammation

The histological analysis revealed that the average of the total HIS in mdr1a−/− mice was the highest in the colon from 16 weeks of age onwards, followed by duodenum, jejunum and ileum. From 22 weeks of age, the average total HIS in the colon was significantly higher in the mdr1a−/− mice compared to the FVB mice (Fig. 1). This was also the case in the duodenum and ileum, starting from 22 weeks of age. The significant differences in the average total HIS between mdr1a−/− mice and FVB mice were less pronounced in the jejunum, with differences between strains only significant at 25 and 29 weeks of age. It was evident that the average of the total HIS in the colon of the mdr1a−/− mice increased up to 25 weeks of age, with no further increase after 27 or 29 weeks of age.

Fig. 1.

Fig. 1

Total histological injury scores in duodenum, jejunum, ileum and colon of mdr1a−/− and FVB mice sampled at 9, 12, 16, 22, 25, 27 and 29 weeks of age. Data are shown as average with LSD bars per sampling group

The location of inflammation was variable between the mdr1a−/− mice. All of the twenty inflamed mdr1a−/− mice had histological signs of inflammation in the colon. Seven of them were only affected in the colon, five of them were affected in all parts of the intestine and the other eight mice showed histological signs of inflammation in both colon and different parts of the small intestine (3 colon and ileum, 2 colon and duodenum, 2 colon, jejunum and duodenum and 1 colon, ileum and duodenum).

Intestinal inflammation was mainly characterized by monocyte and neutrophil infiltration and crypt abscess formation, but also enterocyte loss, ballooning degeneration and hyperplasia. The high-grade inflammatory lesions were transmural involving all layers of the intestinal wall and most areas of the tissue section. There was prominent thickening of the mucosal layer and most crypts had disappeared. The remaining crypts showed epithelial cell hyperplasia and a lack of goblet cells (Fig. 2).

Fig. 2.

Fig. 2

H&E-stained colon sections of an FVB and an mdr1a−/− mouse at 25 weeks of age. a Colon section (×100) from an FVB mouse with a normal, non-inflamed appearance. b Colon section (×100) from an mdr1a−/− mouse with a severely inflamed colon. Lesions involve most of the colon section with monocyte and neutrophil infiltration, crypt abscesses and loss of crypt cells

Myeloperoxidase activity

The MPO activity was measured as a marker of neutrophil infiltration (inflammation) in intact colon samples of both 12 and 25 weeks old FVB and mdr1a−/− mice. The MPO activity was not different between mdr1a−/− and FVB mice at 12 weeks of age, but there was a significant increase (P < 0·05) in MPO activity in colon samples of mdr1a−/− mice compared to FVB mice at 25 weeks of age.

Differential gene expression in colonic epithelial cells of non-inflamed mdr1a−/− and non-inflamed FVB control mice at 12 weeks of age

Differential gene expression was assessed in colonic epithelial scrapings of 12 week old mdr1a−/− and FVB mice. This sampling group was chosen to identify early changes in gene expression, preceding histological inflammatory changes, because no FVB and mdr1a−/− mice from this sampling group showed histological signs of inflammation. Microarray data analysis using two different approaches revealed nine differentially expressed genes between the mdr1a−/− mice compared to the FVB mice at 12 weeks of age (Table 4). ATP-binding cassette sub-family B member 1A (ABCB1A or mdr1a) and ATP-binding cassette sub-family B member 1B (ABCB1B or mdr1b), both involved in drug efflux transport, as well as regenerating islet-derived 3 alpha (REG3A) and regenerating islet-derived 3 gamma (REG3G), both involved in the innate immune response to bacterial colonisation of the gut, were expressed at a lower level in colonic epithelial scrapings of mdr1a−/− mice compared to FVB mice.

Table 4.

Differential gene expression in colonic epithelial cells of 12 week old non-inflamed mdr1a−/− mice and 12 week old non-inflamed FVB mice

Gene name Symbol Refs eq. number Fold-change mdr1a−/− vs. FVB P value Adjusted P value T test ranking
Genes with lower expression in mdr1a−/− mice
 Regenerating islet-derived 3 alpha REG3A NM_011036 7.5 0.02643 0.99997 94th
 Regenerating islet-derived 3 gamma REG3G NM_011260 6.4 0.00657 0.99997 27th
 ATP-binding cassette, sub-family B, member 1A ABCB1A NM_011076 4.0 0.0001 0.43843 5th
 ATP-binding cassette, sub-family B, member 1B ABCB1B NM_011075 3.5 0.00007 0.43843 3rd
Genes with higher expression in mdr1a−/− mice
 Histocompatibility 2, class II, locus Mb1 H2-DMB1 NM_010387 +4.6 0.00004 0.41487 2nd
 ADAM-like, decysin 1 ADAMDEC1 NM_021475 +4.2 0.00254 0.99997 16th
 Major histocompatibility complex, class II, antigen A, beta 1 H2-HB1 NM_207105 +3.2 0.00257 0.99997 17th
 Insulin-like growth factor binding protein 7 IGFBP7 NM_008048 +2.6 0.00009 0.43843 4th
 Periostin, osteoblast specific factor POSTN NM_015784 +1.8 0.00779 0.99997 34th

Furthermore, histocompatibility 2 class II locus Mb1 (H2-DMB1) and major histocompatibility complex class II antigen A beta 1 (H2-HB1), both involved in antigen presentation, ADAM-like decysin 1 (ADAMDEC1), induced during dendritic cell maturation, insulin-like growth factor binding protein 7 (IGFBP7), which can stimulate prostacyclin production, and periostin osteoblast specific factor (POSTN), involved in cell adhesion, were all more highly expressed in colonic epithelial scrapings of mdr1a−/− mice compared to FVB mice (Table 4).

Four genes (REG3A, REG3G, IGFBP7 and H2-DMB1), identified by microarray analysis to be differentially expressed at 12 weeks of age, were randomly chosen for validation using RT-PCR. The differential expression of all of these genes was confirmed using pooled RNA samples and RNA samples from individual animals (Table 6; Fig. 3a–d). However the difference in relative mRNA expression of IGFBP7 was not statistically significant (P = 0.129) between the individual mdr1a−/− and FVB mice.

Table 6.

Validation of microarray data using real-time RT-PCR

Gene symbol Fold-change mdr1a−/− vs. FVB microarray Fold-change mdr1a−/− vs. FVB RT-PCR HPRTa Fold-change mdr1a−/− vs. FVB RT-PCR CANXa
12 weeks 25 weeks 12 weeks 25 weeks 12 weeks 25 weeks
Randomly chosen differentially expressed genes at 12 weeks of age
 REG3A −7.5 −25.3b −13.0 −57.2 −8.6 −31.6
 REG3G −6.4 −6.3b −8.6 −6.2 −7.7 −6.0
 H2-DMB1 +4.6 +2.1c +9.1 +3.8 +9.1 +3.6
 IGFBP7 +2.6 +4.0 +4.1 +9.0 +5.5 +13.9
Randomly chosen differentially expressed genes at 25 weeks of age
 NCF4 +1.6c +4.7 +1.3 +5.8 +1.3 +5.0
 CYP4B1 −1.1c −7.0 −1.1 −7.5 −1.2 −6.8
 SULT1C1 −1.1c −5.9 −1.4 −10.6 −1.3 −8.4

aTwo different house-keeping genes were chosen for normalisation of the data; hypoxanthine phosphoribosyltransferase 1 (HPRT1) and calnexin (CANX)

bMicroarray result was not in the top 100 list of genes ranked by P value using the moderated t-statistics and FDR in Limma, but fulfilled the criteria of the Genespring analysis (FC > 2, P value < 0.05)

cMicroarray result was not statistically significantly different using either GeneSpring or Limma

Fig. 3.

Fig. 3

Differential gene expression of selected genes in colonic epithelial scrapings of individual FVB and mdr1a−/− mice at 12 or 25 weeks of age (FVB12, FVB25, MDR1a12, MDR1a25). The results of the real-time RT-PCR analysis are expressed as relative mRNA expression, using HPRT as a house-keeping gene. Most genes (a REG3A, b REG3G, d H2-DMB1, e CYP4B1, f SULT1C1, g NCF4) were differentially expressed between FVB and mdr1a−/− mice with a P value < 0.05, except c IGFBP7, P = 0.129). The horizontal line indicates the average gene expression within each sampling group

Differential gene expression in colonic epithelial cells of inflamed mdr1a−/− and non-inflamed FVB control mice at 25 weeks of age

Differential gene expression was also assessed in colonic epithelial scrapings of 25 week old inflamed mdr1a−/− and non-inflamed FVB control mice (Table 5). This sampling group was chosen to identify genes with an altered expression during inflammation in mdr1a−/− mice. Microarray data analysis using Genespring and Limma software revealed a clear dysregulation of genes involved in xenobiotic metabolism and transport and the immune response. Genes involved in xenobiotic metabolism such as cytochrome P450 (CYP4B1, CYP2C9, CYP2C18), sulfotransferase (SULT1C1), flavin containing monooxygenase (FMO5), carboxylesterase (CES1), aldo-keto reductase (AKR1C4, AKR1C3) and the transporters mdr1a, mdr1b, solute carrier family 10, member 2 (SLC10A2) and solute carrier family 13, member 1 (SLC13A1) were expressed at a lower level in colonic epithelial scrapings of inflamed mdr1a−/− mice compared to non-inflamed FVB control mice. Inflammatory genes, such as genes involved in the complement system (C1QA, C2, C3), activation of B lymphocytes (SLAM family member 8; SLAMF8), phagocytosis/oxidative burst (neutrophil cytosolic factor 4; NCF4), cell adhesion (integrin beta 7; ITGB7, carcinoembryonic antigen-related cell adhesion molecule 10; CEACAM10) eicosanoid production (IGFBP7) and several chemokines and cytokines (lymphotoxin beta; LTB, chemokine (C-X-C motif) ligand 9 and 10; CXCL9-10, chemokine (C-C motif) ligand 8; CCL8, tumor necrosis factor, alpha-induced protein 2; TNFAIP2 and transcriptional regulators of genes involved in the immune system (nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta; NFKBIZ and CCAAT/enhancer binding protein delta; CEBPD) were more highly expressed in colonic epithelial scrapings of inflamed mdr1a−/− mice compared to non-inflamed FVB control mice. Furthermore, several genes involved in cell proliferation and cell death (cyclin D2; CCND2, RNA binding motif, single stranded interacting protein 1; RBMS1, epithelial membrane protein 3; EMP3, follistatin-like 1; FSTL1, hexokinase 2; HK2, S100 calcium binding protein A4; S100A4, serpin peptidase inhibitor, clade A, member 3G; SERPINA3G) as well as energy metabolism (HK2, SLC16A3, ATPase H+/K+ transporting, non-gastric, alpha polypeptide; ATP12A) were also more highly expressed in colonic epithelial scrapings of inflamed mdr1a−/− mice compared to non-inflamed FVB control mice.

Table 5.

Differential gene expression in colonic epithelial cells of 25 week old inflamed mdr1a−/− mice and 25 week old non-inflamed FVB mice

Gene name Symbol Refs eq. number Fold-change mdr1a−/− vs. FVB P value Adjusted P value T test ranking
Genes with lower expression in mdr1a−/− mice
 ATP-binding cassette, sub-family B, member 1A ABCB1A NM_011076 5.8 0.00001 0.00558 28th
 Cytochrome P450, family 4, subfamily B, polypeptide 1 CYP4B1 NM_007823 7.0 0.00002 0.01184 54th
 Cytochrome P450, family 2, subfamily C, polypeptide 9 CYP2C9 NM_028089 6.9 0.00008 0.01929 95th
 Sulfotransferase family, cytosolic, 1C, member SULT1C1 NM_026935 5.9 0.000008 0.00561 34th
 Hexokinase domain containing 1 HKDC1 NM_145419 5.9 0.000005 0.00480 21th
 Phospholipid scramblase 2 PLSCR2 NM_008880 4.9 0.0000002 0.00333 1st
 Aldo-keto reductase family 1, member C4 AKR1C4 NM_0010137 5.0 0.00007 0.01821 82th
 Solute carrier family 10, member 2 SLC10A2 NM_011388 4.4 0.00003 0.01341 58th
 Flavin containing monooxygenase 5 FMO5 NM_010232 4.4 0.000008 0.00561 32th
 Chromogranin B CHGB NM_007694 4.3 0.000002 0.00448 5th
 Chromogranin A CHGA NM_007693 4.3 0.000005 0.00480 22nd
 ATP-binding cassette, sub-family B, member 1B ABCB1B NM_011075 3.6 0.00003 0.01159 53th
 Bone morphogenic protein 3 BMP3 NM_173404 3.4 0.00002 0.00869 39th
 Carboxylesterase 1 CES1 NM_053200 3.3 0.00004 0.01427 64th
 Cytochrome P450, family 2, subfamily C, polypeptide 18 CYP2C18 NM_010003 3.5 0.00008 0.01929 94th
 Endothelin 2 EDN2 NM_007902 3.3 0.00004 0.01370 61st
 Solute carrier family 13, member 1 SLC13A1 NM_019481 3.2 0.00005 0.01686 72nd
 Hydroxyprostaglandin dehydrogenase 15-(NAD) HPGD NM_008278 3.5 0.000002 0.00448 9th
 Aldo-keto reductase family 1, member C3, AKR1C3 NM_134066 2.8 0.00006 0.01819 79th
 Major histocompatibility complex, class I, F HLA-F NM_008199 3.2 0.00009 0.02096 100th
 Hydroxysteroid dehydrogenase-3, delta <5> 3-beta HSD3B3 NM_001012306 2.9 0.00004 0.01427 68th
 Hypothetical protein MGC17301 MGC17301 NM_027853 2.9 0.00004 0.01349 59th
 Family with sequence similarity 14, member A FAM14A NM_145449 2.8 0.00002 0.00869 40th
 Histocompatibility 2, T region locus 3 H2-T3 NM_008208 2.5 0.000002 0.00448 4th
 Dihydropyrimidine dehydrogenase DPYD NM_170778 2.0 0.00003 0.01185 56th
 Riboflavin kinase RFK NM_019437 2.2 0.00001 0.00864 38th
 Adenosine kinase ADK NM_134079 2.1 0.00005 0.01686 71th
Genes with higher expression in mdr1a−/− mice
 Gelsolin GSN NM_146120 +2.1 0.00003 0.01129 48th
 Integrin, beta 7 ITGB7 NM_013566 +2.0 0.00004 0.01370 63th
 GTP cyclohydrolase 1 GCH1 NM_008102 +2.1 0.00006 0.01819 77th
 RIKEN cDNA 2210407C18 gene 2210407C18Rik NM_144544 +2.4 0.000003 0.00448 14th
 Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta NFKBIZ NM_030612 +2.4 0.000008 0.00561 33nd
 Complement component 2 C2 NM_013484 +2.5 0.00007 0.01925 86th
 Coactosin-like 1 COTL1 NM_028071 +2.7 0.000003 0.00448 15th
 Hypothetical protein FLJ21511 FLJ21511 NM_145560 +2.6 0.00007 0.01919 84th
 Cyclin D2 CCND2 NM_009829 +2.5 0.00004 0.01355 60th
 Glia maturation factor, gamma GMFG NM_022024 +2.6 0.00006 0.01737 74th
 Leucine aminopeptidase 3 LAP3 NM_024434 +2.9 0.000005 0.00514 23rd
 Lymphotoxin beta LTB NM_008518 +2.8 0.00005 0.01485 69th
 CEA-related cell adhesion molecule 10 CEACAM10 NM_007675 +2.9 0.00004 0.01427 66th
 Membrane-spanning 4-domains, subfamily A, member 7 MS4A7 NM_027836 +2.5 0.00006 0.01819 78th
 RNA binding motif, single stranded interacting protein 1 RBMS1 NM_020296 +2.9 0.000004 0.00480 18th
 Epithelial membrane protein 3 EMP3 NM_010129 +2.9 0.00003 0.01129 50th
 Dickkopf homolog 3 DKK3 NM_015814 +2.7 0.00003 0.01129 51st
 Milk fat globule-EGF factor 8 protein MFGE8 NM_008594 +3.3 0.00006 0.01819 75th
 Myosin, light polypeptide 7. regulatory MYL7 NM_022879 +3.4 0.00002 0.00869 42nd
 SLAM family member 8 SLAMF8 NM_029084 +2.8 0.00002 0.01071 47th
 Follistatin-like 1 FSTL1 NM_008047 +2.7 0.00009 0.01977 98th
 Calponin 1, basic, smooth muscle CNN1 NM_009922 +3.3 0.00008 0.01929 90th
 Hexokinase 2 HK2 NM_013820 +4.0 0.000007 0.00549 27th
 Annexin A8 ANXA8 NM_013473 +4.5 0.000003 0.00448 13th
 Zinc finger CCCH-type containing 12A ZC3H12A NM_153159 +3.6 0.000006 0.00520 25th
 CCAAT/enhancer binding protein (C/EBP), delta CEBPD NM_007679 +4.0 0.000001 0.00448 3rd
 Small proline-rich protein 1A SPRR1A NM_009264 +3.7 0.000003 0.00448 10th
 Solute carrier family 16, member 3 SLC16A3 NM_030696 +3.8 0.00002 0.00869 41st
 Collagen, type I, alpha 2 COL1A2 NM_007743 +3.7 0.00003 0.01129 49th
 S100 calcium binding protein A4 S100A4 NM_011311 +4.0 0.000003 0.00448 8th
 Insulin-like growth factor binding protein 7 IGFBP7 NM_008048 +4.0 0.000002 0.00448 7th
 HtrA serine peptidase 1 HTRA1 NM_019564 +3.6 0.000003 0.00448 16th
 Serine (or cysteine) peptidase inhibitor, clade A, member 3G SERPINA3G NM_009251 +4.0 0.00008 0.01929 89th
 Chemokine (C-X-C motif) ligand 9 CXCL9 NM_008599 +4.2 0.00007 0.01925 85th
 Tumor necrosis factor, alpha-induced protein 2 TNFAIP2 NM_009396 +4.2 0.00008 0.01929 96th
 Membrane-spanning 4-domains, subfamily A, member 6B MS4A6B NM_027209 +4.5 0.000002 0.00448 6th
 Neutrophil cytosolic factor 4 NCF4 NM_008677 +4.7 0.00002 0.01071 45th
 Serpin peptidase inhibitor, clade H, member 1 SERPINH1 NM_009825 +5.1 0.00003 0.01185 55th
 Enolase 3 ENO3 NM_007933 +5.9 0.000009 0.00570 36th
 Decorin DCN NM_007833 +6.6 0.00008 0.01929 93rd
 Chemokine (C-X-C motif) ligand 10 CXCL10 NM_021274 +7.6 0.00007 0.01821 83rd
 Chemokine (C-C motif) ligand 8 CCL8 NM_021443 +8.4 0.00009 0.02046 99th
 Complement component 1, q subcomponent, alpha polypeptide C1QA NM_007572 +12.1 0.000008 0.00561 30th
 ATPase, H+/K+ transporting, nongastric, alpha polypeptide ATP12A NM_138652 +10.6 0.0000005 0.00448 2nd
 Complement component 3 C3 NM_009778 +15.0 0.000008 0.00570 35th

Three genes (CYP4B1, SULT1C1 and NCF4), identified by microarray analysis as differentially expressing at 25 weeks of age, were randomly chosen for validation using real-time RT-PCR. The differential expression of all of these genes was confirmed using pooled RNA samples and RNA samples from individual animals (Table 6; Fig. 3e–g).

Discussion

The precise mechanistic defect causing intestinal inflammation in mdr1a−/− mice is unclear but decreased intestinal efflux transport due to defective mdr1a expression may lead to a build-up of bacterial products which can result in an exaggerated or insufficiently suppressed immune response. This study provides new insight into gene expression changes associated with initiation and development of inflammation in mdr1a−/− mice. The anti-inflammatory regeneration islet derived 3A (REG3A) and 3G (REG3G), both involved in the innate immune response to bacterial colonisation of the intestine [14], were expressed at a lower level during inflammation initiation in colonic epithelial cell scrapings of 12 week old non-inflamed mdr1a−/− mice compared to FVB control mice. This was accompanied by a higher expression of genes involved in antigen uptake, presentation and cell adhesion such as H2-DMB1, H2-HB1, ADAMDEC1 and POSTN. Dysregulated genes that have an altered expression during colonic inflammation in mdr1a−/− mice were also identified in this study. This includes several genes involved in both the innate and adaptive immune system that were expressed at a higher level whereas genes involved in xenobiotic metabolism were expressed at a lower level in colonic epithelial cell scrapings of 25 week old inflamed mdr1a−/− mice compared to non-inflamed FVB control mice.

Our study confirms the results of a previous study [2] that the colon was the most highly inflamed area of the whole intestine in mdr1a−/− mice. The inflammation in mdr1a−/− mice was transmural and discontinuous, affecting different layers of the intestinal wall and occurring in different parts of the intestinal tract, revealing similarities to human CD. The time of onset of inflammation was variable; our study: from 16 to 27 weeks of age versus Banner’s study: 6 to 11 weeks of age. The cause of accelerated development of inflammation in mdr1a−/− mice in Banner's study compared to our study is unknown. Banner et al. [2] failed to detect any known pathogen as the causing factor. Stressors related to animal husbandry practices which are not identical between these studies have been shown to affect the development of inflammatory diseases [13].

The nature of the inflammatory response in CD is thought to be dominated by a T-helper cell type 1 response [21], with stimulation of production of cytokines such as interferon-gamma (IFN-γ) which activate macrophages and induce killer mechanisms, including cytotoxic T cells [5]. We measured plasma cytokine levels using Bead Array and observed an increase in IFN-γ in plasma of 25 week old inflamed mdr1a−/− mice compared to FVB control mice. This result was however not significant due to the high variation between the animals (data not shown). It does, however, provide further support for a similarity to human CD as significant increases in both colonic IFN-γ and mRNA for IFN-γ were found in mdr1a−/− mice compared to mdr1a+/+ mice in studies of both Banner et al. [2] and Maggio-Price et al. [18].

The inflammatory lesions in mdr1a−/− mice were dominated by agranular monocytes and granular neutrophils, both capable of phagocytosis of toxins and bacteria and inducing an oxidative burst [5]. Neutrophils have been implicated as possible mediators of mucosal injury and indicate an acute inflammatory response [9]. Our visual observations confirm acute inflammation in mdr1a−/− mice. When mice developed disease symptoms (diarrhea and weight loss) they needed to be sampled promptly, as it was unlikely they would have survived the inflammatory distress. The total HIS in colon did not increase over time after 25 weeks of age, which also represents the incidence of acute inflammation rather than a chronic accumulation of inflammation over time. The MPO activity, measured as an independent marker of neutrophil infiltration, was also increased in intact colon samples of 25 week old inflamed mdr1a−/− mice compared to non-inflamed FVB control mice. Furthermore the gene neutrophil cytosolic factor 4 (NCF4) (alias p40-phox) was expressed at a higher level in colonic epithelial cell scrapings of 25 week old inflamed mdr1a−/− mice. NCF4 is a component of the NADPH-oxidase multiple component enzyme system [15], responsible for the oxidative burst in which electrons are transported from NADPH to molecular oxygen, generating reactive oxygen intermediates crucial for host defense. This result also agreed with the increased neutrophil infiltration in colonic epithelial cells of inflamed mdr1a−/− mice.

REG3A and REG3G were expressed at a lower level in colonic epithelial cell scrapings of 12 week old non-inflamed mdr1a−/− mice compared to FVB control mice. Regeneration islet derived (REG) genes, the murine orthologues of human pancreatitis-associated proteins (PAP), are part of the innate immune response and have been shown to be induced after colonisation of germ-free SCID mice with commensal bacteria [14]. Recently it was shown that PAP1 has functional similarities to the cytokine interleukin 10 (IL-10) and can inhibit the inflammatory response by blocking NFκB activation [7]. Down-regulation of the anti-inflammatory REG (PAP) genes in non-inflamed mdr1a−/− mice of 12 weeks of age suggests that an insufficiently suppressed immune response could be crucial to the initiation and development of intestinal inflammation in mdr1a−/− mice. Down-regulation of the anti-inflammatory REG (PAP) genes could lead to more active NFκB and more transcriptional activation of pro-inflammatory genes such as adhesion molecules [26] and MHC class II genes [10]. The lower expression of the REG (PAP) genes in colonic epithelial cell scrapings of 12 week old non-inflamed mdr1a−/− mice compared to non-inflamed FVB control mice was accompanied by a higher expression of a cell adhesion molecule (POSTN) and two MHC class II genes (H2-DMB1 and H2-HB1), suggesting more active NFκB in mdr1a−/− mice.

Other inflammatory genes that are more highly expressed in 25 week old inflamed mdr1a−/− mice compared to FVB control mice include those involved in the complement system (C1QA, C2, C3), activation of B lymphocytes (SLAMF8), cell adhesion (ITGB7, CEACAM10), eicosanoid production (IGFBP7) and several chemo- and cytokines (LTB, CXCL9, TNFAIP2, CXCL10, CCL8). Two transcriptional regulators of genes involved in the immune system NFKBIZ and CEBPD were also expressed at a higher level in inflamed mdr1a−/− mice. Several similar genes such as complement component genes (C2, CR2, C4a), a neutrophil chemotaxin (NCF1), an integrin (ITGB2) and the cytokines LTB [6], CXCL1, CXCL3, CXCL8 and CCL20 [22] were also found to be more highly expressed in colonic and mucosal biopsies of patients with IBD.

Using DNA microarrays, a cluster of strongly down-regulated genes has been identified in the colon of patients with IBD [16]. This cluster of genes was composed of cellular detoxification and defense genes, such as cytochrome P450 enzymes, a carboxylesterase (CES2), glutathione S-transferases, sulfotransferases and ABC transporters. Our data are in good agreement with these human studies as several cytochrome P450s (CYP4B1, CYP2C9, CYP2C18), a sulfotransferase (SULT1C1), a carboxylesterase (CES1) and the ABC transporter ABCB1B (mdr1b) were strongly down-regulated in the colon of inflamed mdr1a−/− mice, as were several other xenobiotic metabolism genes such as aldo-keto reductases (AKR1C4, AKR1C3) and a flavin containing monooxygenase (FMO5). A decrease in the expression of detoxification enzymes and transporters is probably a secondary effect. Inflammation and infection have long been known to downregulate the activity and expression of drug-metabolizing enzymes and transporters although regulation of the phase I and phase II enzymes and transporters in inflammation is very complex [1].

In summary, our study provides further evidence of similarity in both the nature and location of intestinal inflammation in mdr1a−/− mice with that of human IBD, in particular CD. In addition, similar gene expression changes of pro-inflammatory genes and detoxification enzymes in inflamed mdr1a−/− mice compared to human IBD supports the use of this in vivo model to study IBD. Using DNA microarrays and RT-PCR we were also able to gain more insight into the nature of the epithelial response during inflammation initiation in mdr1a−/− mice. We found a down-regulation of the anti-inflammatory REG (PAP) genes in colonic epithelial cell scrapings of 12 week old non-inflamed mdr1a−/− mice which suggest that an insufficiently suppressed immune response could be crucial to the initiation and development of intestinal inflammation in mdr1a−/− mice. Our study contributes to the development of the mdr1a−/− mice model for use in nutrigenomics experiments to investigate the anti-inflammatory potential of food components for the prevention or amelioration of inflammatory lesions and related gene expression changes in mdr1a−/− mice.

Acknowledgments

Many thanks to Janice Rhodes and Hannah Smith (Crop and Food Research) for assistance with the mouse trial and Ric Broadhurst, Jason Peters, Bruce Sinclair and Kate Broadley (AgResearch Limited) for technical support throughout the study. The authors would also like to thank Julian Heyes and Juliet Sutherland (Crop and Food Research) for the valuable discussions and Katia Nones (Crop and Food Research) for proof-reading and editing the manuscript. This study is part of Nutrigenomics New Zealand, a collaboration between AgResearch, Crop & Food Research, HortResearch and The University of Auckland that is largely funded by the Foundation for Research, Science and Technology. Matthew Barnett is funded by a Foundation for Research, Science and Technology Postdoctoral Fellowship.

Abbreviations

ABCB

ATP-binding cassette sub-family B

CANX

Calnexin

CYP

Cytochrome P450

IBD

Inflammatory Bowel Diseases

CD

Crohn’s Disease

HPRT1

Hypoxanthine phosphoribosyltransferase 1

HIS

Histological injury score

IGFBP7

Insulin-like growth factor binding protein 7

IFN-γ

Interferon gamma

MPO

Myeloperoxidase

MDR

Multidrug resistance

NCF4

Neutrophil cytosolic factor 4

REG3

Regenerating islet-derived 3

RT-PCR

Real time polymerase chain reaction

SNP

Single nucleotide polymorphism

SULT

Sulfotransferase

UC

Ulcerative Colitis

References

  • 1.Aitken AE, Richardson TA, Morgan ET (2006) Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol 46:123–149 [DOI] [PubMed]
  • 2.Banner KH, Cattaneo C, Le Net JL, Popovic A, Collins D, Gale JD (2004) Macroscopic, microscopic and biochemical characterisation of spontaneous colitis in a transgenic mouse, deficient in the multiple drug resistance 1a gene. Br J Pharmacol 143:590–598 [DOI] [PMC free article] [PubMed]
  • 3.Bilsborough J, Viney JL (2004) Out, out darn toxin: the role of MDR in intestinal homeostasis. Gastroenterology 127:339–340 [DOI] [PubMed]
  • 4.Brant SR, Panhuysen CI, Nicolae D, Reddy DM, Bonen DK, Karaliukas R, Zhang L, Swanson E, Datta LW, Moran T, Ravenhill G, Duerr RH, Achkar JP, Karban AS, Cho JH (2003) MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet 73:1282–1292 [DOI] [PMC free article] [PubMed]
  • 5.Cummings JH, Antoine JM, Azpiroz F, Bourdet-Sicard R, Brandtzaeg P, Calder PC, Gibson GR, Guarner F, Isolauri E, Pannemans D, Shortt C, Tuijtelaars S, Watzl B (2004) PASSCLAIM—gut health and immunity. Eur J Nutr 43(Suppl 2):II118–II173 [DOI] [PubMed]
  • 6.Dieckgraefe BK, Stenson WF, Korzenik JR, Swanson PE, Harrington CA (2000) Analysis of mucosal gene expression in inflammatory bowel disease by parallel oligonucleotide arrays. Physiol Genom 4:1–11 [DOI] [PubMed]
  • 7.Folch-Puy E, Granell S, Dagorn JC, Iovanna JL, Closa D (2006) Pancreatitis-associated protein I suppresses NF-kappa B activation through a JAK/STAT-mediated mechanism in epithelial cells. J Immunol 176:3774–3779 [DOI] [PubMed]
  • 8.Gaya DR, Russell RK, Nimmo ER, Satsangi J (2006) New genes in inflammatory bowel disease: lessons for complex diseases? Lancet 367:1271–1284 [DOI] [PubMed]
  • 9.Grisham MB, Benoit JN, Granger DN (1990) Assessment of leukocyte involvement during ischemia and reperfusion of intestine. Methods Enzymol 186:729–742 [DOI] [PubMed]
  • 10.Haller D (2006) Intestinal epithelial cell signalling and host-derived negative regulators under chronic inflammation: to be or not to be activated determines the balance towards commensal bacteria. Neurogastroenterol Motil 18:184–199 [DOI] [PubMed]
  • 11.Ho GT, Moodie FM, Satsangi J (2003) Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut 52:759–766 [DOI] [PMC free article] [PubMed]
  • 12.Ho GT, Soranzo N, Nimmo ER, Tenesa A, Goldstein DB, Satsangi J (2006) ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach. Hum Mol Genet 15:797–805 [DOI] [PubMed]
  • 13.Jessop DS, Douthwaite DA, Conde GL, Lightman SL, Dayan SM, Harbuz MS (1997) Effects of acute stress or centrally injected interleukin-1beta on neuropeptide expression in the immune system. Stress 2:133–144 [DOI] [PubMed]
  • 14.Keilbaugh SA, Shin ME, Banchereau RF, McVay LD, Boyko N, Artis D, Cebra JJ, Wu GD (2005) Activation of RegIIIbeta/gamma and interferon gamma expression in the intestinal tract of SCID mice: an innate response to bacterial colonisation of the gut. Gut 54:623–629 [DOI] [PMC free article] [PubMed]
  • 15.Kuribayashi F, Nunoi H, Wakamatsu K, Tsunawaki S, Sato K, Ito T, Sumimoto H (2002) The adaptor protein p40(phox) as a positive regulator of the superoxide-producing phagocyte oxidase. EMBO J 21:6312–6320 [DOI] [PMC free article] [PubMed]
  • 16.Langmann T, Moehle C, Mauerer R, Scharl M, Liebisch G, Zahn A, Stremmel W, Schmitz G (2004) Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology 127:26–40 [DOI] [PubMed]
  • 17.Lawrance IC, Fiocchi C, Chakravarti S (2001) Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes. Hum Mol Genet 10:445–456 [DOI] [PubMed]
  • 18.Maggio-Price L, Shows D, Waggie K, Burich A, Zeng W, Escobar S, Morrissey P, Viney JL (2002) Helicobacter bilis infection accelerates and H. hepaticus infection delays the development of colitis in multiple drug resistance-deficient (mdr1a−/−) mice. Am J Pathol 160:739–751 [DOI] [PMC free article] [PubMed]
  • 19.Mathew CG, Lewis CM (2004) Genetics of inflammatory bowel disease: progress and prospects. Hum Mol Genet 13(Spec No 1):R161–R168 [DOI] [PubMed]
  • 20.Panwala CM, Jones JC, Viney JL (1998) A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 161:5733–5744 [PubMed]
  • 21.Podolsky DK (2002) The current future understanding of inflammatory bowel disease. Best Pract Res Clin Gastroenterol 16:933–943 [DOI] [PubMed]
  • 22.Puleston J, Cooper M, Murch S, Bid K, Makh S, Ashwood P, Bingham AH, Green H, Moss P, Dhillon A, Morris R, Strobel S, Gelinas R, Pounder RE, Platt A (2005) A distinct subset of chemokines dominates the mucosal chemokine response in inflammatory bowel disease. Aliment Pharmacol Ther 21:109–120 [DOI] [PubMed]
  • 23.Reeves PG, Nielsen FH, Fahey GC Jr (1993) AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 123:1939–1951 [DOI] [PubMed]
  • 24.Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood–brain barrier and to increased sensitivity to drugs. Cell 77:491–502 [DOI] [PubMed]
  • 25.Schwab M, Schaeffeler E, Marx C, Fromm MF, Kaskas B, Metzler J, Stange E, Herfarth H, Schoelmerich J, Gregor M, Walker S, Cascorbi I, Roots I, Brinkmann U, Zanger UM, Eichelbaum M (2003) Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 124:26–33 [DOI] [PubMed]
  • 26.Tak PP, Firestein GS (2001) NF-kappaB: a key role in inflammatory diseases. J Clin Invest 107:7–11 [DOI] [PMC free article] [PubMed]
  • 27.Yantiss RK, Odze RD (2006) Diagnostic difficulties in inflammatory bowel disease pathology. Histopathology 48:116–132 [DOI] [PubMed]

Articles from Genes & Nutrition are provided here courtesy of BMC

RESOURCES